Type 4a myocardial infarction: Incidence, risk factors, and long-term outcomes

Xiaoyu Yang1,2, Hector Tamez1,2, Carol Lai1,2

  • 1Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Insights

Periprocedural myocardial infarction (Type 4a MI) and myocardial injury following percutaneous coronary intervention (PCI) are common. These events are linked to more complex procedures and increased risks of death or recurrent MI within one year.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Clinical Outcomes Research

Background:

  • The 2012 Third Universal Definition of myocardial infarction (MI) Type 4a requires prospective evaluation in real-world settings.
  • Understanding periprocedural MI (Type 4a) incidence and outcomes after percutaneous coronary intervention (PCI) is crucial.

Purpose of the Study:

  • To determine the incidence of Type 4a MI and myocardial injury in patients undergoing PCI.
  • To assess the one-year clinical outcomes associated with Type 4a MI and myocardial injury post-PCI.

Main Methods:

  • A cohort of 516 patients undergoing PCI for stable coronary disease or non-ST elevation acute coronary syndrome was studied.
  • Data were collected from the National Cardiovascular Data Registry, electronic medical records, and telephone interviews.
  • One-year outcomes included all-cause mortality, recurrent MI, and repeat coronary revascularization.

Main Results:

  • 10.3% of patients met criteria for Type 4a MI, and 22.5% experienced myocardial injury.
  • Patients with Type 4a MI or myocardial injury underwent more complex PCI, indicated by higher stent use and rotational atherectomy.
  • While Type 4a MI was not linked to mortality, both Type 4a MI and myocardial injury groups had higher rates of death or recurrent MI at one year compared to controls.

Conclusions:

  • Type 4a MI and myocardial injury are frequent occurrences after PCI.
  • These events are associated with more complex procedures and an increased risk of adverse cardiovascular events within one year.
  • Further research may refine management strategies for patients experiencing periprocedural MI or injury.
Abstract

Related Concept Videos

Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
336
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.5K
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
535
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
376
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
386
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
618